Latest Breaking News On - Microbiome center - Page 10 : comparemela.com

The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635 9 million by 2028

/PRNewswire/ The newly published report titled "Global Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market– By Trends, Industry.

United statesNew zealandSouth africaSwitzerland generalSouth koreaPriyanka tilekarAsia pacificArranta bioAssembly biosciencesMicrobiome centerCobra biologicsList biological labs incHansen holdingThermo fisherDanish medicines agency at bactheraLarge companies

Tennessee s hospitalization increases worse than any other time in pandemic | 1011 The Beat

Tennessee s hospitalization increases worse than any other time in pandemic | 1011 The Beat
iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.

United statesVanderbilt microbiome centerMicrobiome centerUpper cumberlandVolunteer stateஒன்றுபட்டது மாநிலங்களில்மேல் கம்பர்லேண்ட்தன்னார்வ நிலை

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding. ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings. ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.

Namasivayam ambalavananAndrew oconnorC vivek lalJon nugentBraxton goodrichEmily hendersonScott bushAmit gaggarSanjay singhMicrobiome centerBirmingham business allianceResbiotic incDivision of neonatologyLal pulmonary microbiome labResbiotech innovation instituteUniversity of alabama at birmingham

UAB spinoff to treat chronic respiratory disease announces $3 million seed funding

Credit: UAB BIRMINGHAM, Ala. - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding. ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings. ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.

Namasivayam ambalavananAndrew oconnorC vivek lalJon nugentBraxton goodrichScott bushAmit gaggarSanjay singhMicrobiome centerResbiotic incDivision of neonatologyLal pulmonary microbiome labInnovation for the birmingham business allianceResbiotech innovation instituteUniversity of alabama at birminghamTimberline holdings

ResBiotic Raises $3M in Seed Funding

Resbiotic, Inc., a Bilmingham, Ala.-based biotech startup, raised $3M in seed funding. The round was funded from a private equity syndicate led by Timberline Holdings. Braxton Goodrich (Timberline Holdings) will serve on the ResBiotic Board of Directors. The company intends to use the funds for the development and commercialization of probiotic formulations for lung health. ResBiotic is the flagship company of ResBiotech Innovation Institute, founded by physician scientist Dr. C Vivek Lal in 2020. ResBiotic’s first product, a medical food that targets the gut-lung axis, was developed in Dr. Lal’s Pulmonary Microbiome Lab at UAB with research and expertise from the university’s Microbiome Center, Lung Health Center and Translational Research in Normal & Disordered Development (TReNDD) program. The proprietary probiotic blend has been shown to reduce neutrophilic inflammation in individuals with chronic respiratory conditions. The company’s research and development

Vivek lalNamasivayam ambalavananAndrew oconnorScott bushAmit gaggarBraxton goodrichSanjay singhMicrobiome centerResbiotic incLal pulmonary microbiome labResbiotech innovation instituteTimberline holdingsTranslational research in normal disordered development treHarvard universityLung health centerResbiotic board